RESEARCH & DISCOVERY | Ozempic and Wegovy May Slow Biological Ageing

TheDigger Intelligence Unit

The Breakthrough

Semaglutide, the active ingredient in Ozempic and Wegovy, is already transforming treatment for obesity and diabetes. Now, scientists report it may also slow biological ageing. In a randomized, placebo‑controlled trial of 108 adults with HIV‑associated lipohypertrophy, weekly semaglutide injections reduced DNA methylation markers tied to accelerated aging.

This is the first clinical evidence in humans that a GLP‑1 receptor agonist could influence the pace of ageing itself.

What the Study Found

Slower ageing across multiple “epigenetic clocks” — tools that measure DNA methylation patterns linked to inflammation, metabolism, and organ health.

9% slower biological ageing on the DunedinPACE clock, a widely used measure of cellular ageing.

Reduced risk signals for age‑related disease and mortality on the PCGrimAge clock.

Broader systemic effects across blood, brain, heart, kidney, liver, and metabolic pathways.

Why It Matters

People living with HIV often experience accelerated ageing despite effective antiretroviral therapy. By calming inflammation and reducing harmful fat deposits, semaglutide may help counteract this process. Researchers believe these mechanisms — lowering visceral and ectopic fat, reducing immune activation, and possibly reprogramming cells — could extend beyond HIV patients to the general population.

Supporting Evidence

A related pilot study in patients with HIV and fatty liver disease found:

42% slowed biological ageing over 24 weeks.

Longer telomeres in nearly half of participants, suggesting improved cellular resilience.

Better physical function, including faster walking speeds.

Together, these findings strengthen the case that GLP‑1 drugs may influence ageing biology.

The Caveats

Scientists caution against calling semaglutide an “anti-ageing drug.” The evidence is early, limited in scope, and focused on HIV patients. Larger, long‑term trials are needed to confirm whether benefits extend to broader populations, how durable they are, and which patients stand to gain the most.

The Road Ahead

The Stein Institute for Research on Ageing is developing personalised “ageing dashboards” using epigenetic clocks to track biological age more precisely. The hope is to design individualised treatments that target the root causes of age‑related disease.

If confirmed, GLP‑1 drugs could shift from being primarily weight‑loss and diabetes medications to tools for extending healthspan — the years lived in good health.